Publicacions en col·laboració amb investigadors/es de University of Glasgow (25)

2024

  1. Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

    Annals of Surgical Oncology, Vol. 31, Núm. 10, pp. 6495-6503

  2. Recommendations on maximising the clinical value of tissue in the management of patients with intrahepatic cholangiocarcinoma

    JHEP Reports, Vol. 6, Núm. 6

2023

  1. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. Heterogeneity of Cholangiocarcinoma Immune Biology

    Cells, Vol. 12, Núm. 6

  4. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis

    Cells, Vol. 12, Núm. 16

2022

  1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  2. Bridging the equity gap in patient education: the biliary tract cancer BABEL project

    The Lancet Oncology

  3. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  4. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  5. Interferon-stimulated gene 15 pathway is a novel mediator of endothelial dysfunction and aneurysms development in angiotensin II infused mice through increased oxidative stress

    Cardiovascular research, Vol. 118, Núm. 16, pp. 3250-3268

  6. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  2. Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System

    Hepatology, Vol. 73, Núm. 6, pp. 2311-2325

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  4. REPLY:

    Hepatology

  5. REPLY:

    Hepatology

2020

  1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  2. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

    British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059

  3. Non-canonical Wnt signalling regulates scarring in biliary disease via the planar cell polarity receptors

    Nature Communications, Vol. 11, Núm. 1